<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TEST" NEWID="15998" OLDID="5036" TOPICS="NO">
<DATE> 9-APR-1987 16:52:22.24</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   F
   f2640 reute
r f BC-SMITHKLINE-&lt;SKB&gt;-VACC   04-09 0095</UNKNOWN>
<TEXT> 
<TITLE>SMITHKLINE &lt;SKB&gt; VACCINE GETS APPROVAL OVERSEAS</TITLE>
<DATELINE>    PHILADELPHIA, April 9 - </DATELINE><BODY>Smithkline Beckman Corp said its
genetically engineered hepatitis B vaccine has received
regulatory approval for marketing in Switzerland and
Luxembourg.
    The vaccine, called Engerix-B, has been approved in several
other countries, including Belgium and Hong Kong.
    Smithkline said it is currently considering marketing
avenues in the United States.
    Merck and Co &lt;MRK&gt; also has a genetically engineered
vaccine being marketed in several foreign markets, according to
industry sources.
 Reuter
 </BODY></TEXT>
</REUTERS>